Wells Fargo & Company Has Lowered Expectations for ResMed (NYSE:RMD) Stock Price

ResMed (NYSE:RMD) had its target price decreased by research analysts at Wells Fargo & Company from $225.00 to $215.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 1.68% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Evercore set a $255.00 target price on shares of ResMed and gave the stock an “outperform” rating in a report on Monday, April 13th. UBS Group reiterated a “buy” rating and set a $300.00 price target on shares of ResMed in a report on Tuesday, July 21st. Citigroup reissued a “neutral” rating and issued a $235.00 price objective (down from $270.00) on shares of ResMed in a research report on Sunday, July 12th. Morgan Stanley reissued an “equal weight” rating and issued a $230.00 price objective (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. Finally, Robert W. Baird set a $225.00 target price on ResMed in a research report on Friday, May 1st. Seven analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $244.50.

ResMed Price Performance

ResMed stock traded down $11.79 during midday trading on Friday, reaching $211.45. 624,182 shares of the stock traded hands, compared to its average volume of 1,285,624. The stock has a market cap of $30.67 billion, a P/E ratio of 20.40, a PEG ratio of 1.36 and a beta of 0.76. The stock’s fifty day moving average is $200.06 and its 200-day moving average is $222.30. The company has a quick ratio of 2.33, a current ratio of 3.01 and a debt-to-equity ratio of 0.06. ResMed has a 12 month low of $180.26 and a 12 month high of $293.81.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.89 by $0.06. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.46 billion. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.55 EPS. As a group, equities research analysts anticipate that ResMed will post 11.14 EPS for the current year.

Insider Activity

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total value of $1,090,783.05. Following the transaction, the chief executive officer directly owned 466,223 shares in the company, valued at $101,893,036.65. This represents a 1.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 8,000 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,800,000.00. Following the completion of the transaction, the director owned 52,773 shares in the company, valued at $11,873,925. This represents a 13.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 17,982 shares of company stock worth $3,858,837 in the last ninety days. 0.65% of the stock is currently owned by insiders.

Institutional Trading of ResMed

Large investors have recently modified their holdings of the company. State Street Corp raised its position in ResMed by 1.2% during the 4th quarter. State Street Corp now owns 6,625,408 shares of the medical equipment provider’s stock valued at $1,595,862,000 after purchasing an additional 76,244 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of ResMed by 0.7% in the 1st quarter. Bank of New York Mellon Corp now owns 4,925,386 shares of the medical equipment provider’s stock worth $1,105,651,000 after buying an additional 34,732 shares during the period. Geode Capital Management LLC grew its position in shares of ResMed by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 4,302,906 shares of the medical equipment provider’s stock worth $1,032,877,000 after buying an additional 51,218 shares in the last quarter. Morgan Stanley grew its position in shares of ResMed by 25.0% during the 4th quarter. Morgan Stanley now owns 2,891,697 shares of the medical equipment provider’s stock worth $696,523,000 after buying an additional 578,559 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of ResMed by 5.2% during the fourth quarter. Northern Trust Corp now owns 1,785,384 shares of the medical equipment provider’s stock valued at $430,045,000 after buying an additional 87,502 shares during the period. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Key ResMed News

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, above analyst expectations of approximately $2.89–$2.90 and up from $2.55 a year earlier. Revenue rose 8.6% year over year to $1.46 billion, supporting the company’s continued growth. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company raised its dividend alongside its strong fourth-quarter and full-year fiscal 2026 results, potentially increasing its appeal to income-focused investors. ResMed Posts Strong Q4 Earnings and Lifts Dividend
• Neutral Sentiment: Analyst opinion remains cautious. ResMed has an average “Hold” rating, with several firms recently reducing price targets, although the consensus target of $246.25 remains above the current trading level. ResMed Receives Average Hold Rating
• Neutral Sentiment: Investors are also weighing industry risks, including tariffs, inflation and pressure on hospital spending, which could affect medtech demand and margins despite ResMed’s profitability. Medtech Earnings Season Preview
• Negative Sentiment: Director Peter Farrell sold 8,000 shares for $1.8 million, reducing his stake by 13.16%. Because the sale occurred under a pre-arranged Rule 10b5-1 plan, it is a limited signal of insider confidence, but it may still create modest selling pressure. SEC Insider Trading Filing

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.